CZ2019153A3 - Mikročástice na bázi esterových derivátů hyaluronanu, způsob jejich výroby, kompozice, které je obsahují a jejich použití - Google Patents

Mikročástice na bázi esterových derivátů hyaluronanu, způsob jejich výroby, kompozice, které je obsahují a jejich použití

Info

Publication number
CZ2019153A3
CZ2019153A3 CZ2019-153A CZ2019153A CZ2019153A3 CZ 2019153 A3 CZ2019153 A3 CZ 2019153A3 CZ 2019153 A CZ2019153 A CZ 2019153A CZ 2019153 A3 CZ2019153 A3 CZ 2019153A3
Authority
CZ
Czechia
Prior art keywords
hyaluronan
retinoic acid
formula
trans retinoic
ester derivatives
Prior art date
Application number
CZ2019-153A
Other languages
English (en)
Inventor
Gloria HUERTA ANGELES
Martina Brandejsová
Paulina ORZOL
Kateřina Kopecká
Vojtěch Pavlík
Jaroslav NOVOTNÝ
Iva Dolečková
Kristina Nešporová
Vladimír Velebný
Original Assignee
Contipro A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contipro A.S. filed Critical Contipro A.S.
Priority to CZ2019-153A priority Critical patent/CZ2019153A3/cs
Priority to KR1020217032731A priority patent/KR20210142133A/ko
Priority to BR112021018197A priority patent/BR112021018197A2/pt
Priority to EP20722216.7A priority patent/EP3938407A1/en
Priority to US17/439,284 priority patent/US20220249352A1/en
Priority to JP2021555356A priority patent/JP2022526882A/ja
Priority to PCT/CZ2020/050010 priority patent/WO2020182239A1/en
Publication of CZ2019153A3 publication Critical patent/CZ2019153A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/65—Characterized by the composition of the particulate/core
    • A61K2800/654—The particulate/core comprising macromolecular material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mikročástice na bázi esterových derivátů hyaluronanu obsahující konjugát kyseliny all-trans retinové a hyaluronanu obecného vzorce I: kde n je celé číslo v rozmezí 1 až 5000 dimerů, R4 je H+ nebo farmaceuticky přijatelná sůl, R3 je −H nebo zbytek all-trans retinové kyseliny vzorce II, kde je místo kovalentní vazby zbytku kyseliny all-trans retinové vzorce II, za předpokladu, že alespoň jeden R3 konjugátu je zbytek all-trans retinové kyseliny vzorce II a kde stupeň substituce zbytku kyseliny all-trans retinové vzorce II v konjugátu hyaluronanu je v rozmezí od 0,1 do 8 %.
CZ2019-153A 2019-03-14 2019-03-14 Mikročástice na bázi esterových derivátů hyaluronanu, způsob jejich výroby, kompozice, které je obsahují a jejich použití CZ2019153A3 (cs)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CZ2019-153A CZ2019153A3 (cs) 2019-03-14 2019-03-14 Mikročástice na bázi esterových derivátů hyaluronanu, způsob jejich výroby, kompozice, které je obsahují a jejich použití
KR1020217032731A KR20210142133A (ko) 2019-03-14 2020-03-13 히알루로난 에스테르 유도체 기재의 마이크로입자, 그의 제조 방법, 그를 포함하는 조성물 및 그의 용도
BR112021018197A BR112021018197A2 (pt) 2019-03-14 2020-03-13 Micropartículas à base de ésteres derivados de hialuronano, método de produção das micropartículas e composição compreendendo micropartículas de um conjugado de ácido retinóico all-trans e hialuronano
EP20722216.7A EP3938407A1 (en) 2019-03-14 2020-03-13 Microparticles based on ester derivatives of hyaluronan, method of production, composition comprising thereof and use thereof
US17/439,284 US20220249352A1 (en) 2019-03-14 2020-03-13 Microparticles based on ester derivatives of hyaluronan, method of production, composition comprising thereof and use thereof
JP2021555356A JP2022526882A (ja) 2019-03-14 2020-03-13 ヒアルロナンのエステル誘導体をベースとするマイクロ粒子，その製造方法，前記マイクロ粒子を含む組成物，及びその使用
PCT/CZ2020/050010 WO2020182239A1 (en) 2019-03-14 2020-03-13 Microparticles based on ester derivatives of hyaluronan, method of production, composition comprising thereof and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CZ2019-153A CZ2019153A3 (cs) 2019-03-14 2019-03-14 Mikročástice na bázi esterových derivátů hyaluronanu, způsob jejich výroby, kompozice, které je obsahují a jejich použití

Publications (1)

Publication Number Publication Date
CZ2019153A3 true CZ2019153A3 (cs) 2020-09-23

Family

ID=70470724

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2019-153A CZ2019153A3 (cs) 2019-03-14 2019-03-14 Mikročástice na bázi esterových derivátů hyaluronanu, způsob jejich výroby, kompozice, které je obsahují a jejich použití

Country Status (7)

Country Link
US (1) US20220249352A1 (cs)
EP (1) EP3938407A1 (cs)
JP (1) JP2022526882A (cs)
KR (1) KR20210142133A (cs)
BR (1) BR112021018197A2 (cs)
CZ (1) CZ2019153A3 (cs)
WO (1) WO2020182239A1 (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102441798B1 (ko) * 2021-07-15 2022-09-08 아주대학교산학협력단 히알루론산 복합체를 포함하는 피부 질환 예방 또는 치료용 약학 조성물
CN117964796A (zh) * 2024-03-29 2024-05-03 成都格纯生物医药有限公司 一种透明质酸视黄酸酯衍生物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTS20010017A1 (it) * 2001-07-17 2003-01-17 Ct Ricerche Polytech Soc Coop Esteri polisaccaridici di acido retinoico.

Also Published As

Publication number Publication date
JP2022526882A (ja) 2022-05-27
KR20210142133A (ko) 2021-11-24
BR112021018197A2 (pt) 2021-11-16
WO2020182239A1 (en) 2020-09-17
EP3938407A1 (en) 2022-01-19
US20220249352A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
MX2020004423A (es) Nuevos compuestos de sulfonamida carboxamida.
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
MA42232A (fr) Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant
MX2020000404A (es) Inhibidores de tirosina quinasa de bazo (syk).
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
CZ2019153A3 (cs) Mikročástice na bázi esterových derivátů hyaluronanu, způsob jejich výroby, kompozice, které je obsahují a jejich použití
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
FR3037958B1 (fr) Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
BR112015027164A2 (pt) novos compostos com tripla atividade de trombólise, antitrombótica e neutralização de radical, e sua síntese, nanoestrutura e uso
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
MA40886B1 (fr) Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
BR112021018924A2 (pt) Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
CO2021014210A2 (es) Compuestos de pirrol
MA38854B1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
PH12021551086A1 (en) Pharmaceutical formulations of cyclosporine analogs
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
CL2020001156A1 (es) Formulaciones de liberación prolongada para aplicaciones intra-articulares.
BR112014015430A8 (pt) formulação oftálmica
MA40110A1 (fr) Dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine en tant que médicaments anticancéreux
MX362192B (es) Derivado de glicinamida alfa-sustituida.
BR112015001989A8 (pt) uso de butilidenoftalida (bp)
EA202190890A1 (ru) Получение замещенных ароматических соединений и их применение в фармацевтике